Eli Lilly Retained Earnings (Accumulated Deficit) 2010-2024 | LLY
Eli Lilly retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Eli Lilly retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $13.627B, a 32.18% increase year-over-year.
- Eli Lilly retained earnings (accumulated deficit) for 2023 were $10.312B, a 2.69% increase from 2022.
- Eli Lilly retained earnings (accumulated deficit) for 2022 were $10.043B, a 12.1% increase from 2021.
- Eli Lilly retained earnings (accumulated deficit) for 2021 were $8.959B, a 14.41% increase from 2020.
Eli Lilly Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$10,312 |
| 2022 |
$10,043 |
| 2021 |
$8,959 |
| 2020 |
$7,830 |
| 2019 |
$4,920 |
| 2018 |
$11,396 |
| 2017 |
$13,894 |
| 2016 |
$16,046 |
| 2015 |
$16,012 |
| 2014 |
$16,483 |
| 2013 |
$16,992 |
| 2012 |
$16,088 |
| 2011 |
$14,898 |
| 2010 |
$12,733 |
| 2009 |
$9,830 |
Eli Lilly Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-09-30 |
$13,627 |
| 2024-06-30 |
$13,178 |
| 2024-03-31 |
$12,554 |
| 2023-12-31 |
$10,312 |
| 2023-09-30 |
$10,310 |
| 2023-06-30 |
$10,369 |
| 2023-03-31 |
$10,639 |
| 2022-12-31 |
$10,043 |
| 2022-09-30 |
$10,007 |
| 2022-06-30 |
$8,556 |
| 2022-03-31 |
$9,369 |
| 2021-12-31 |
$8,959 |
| 2021-09-30 |
$9,639 |
| 2021-06-30 |
$8,530 |
| 2021-03-31 |
$9,181 |
| 2020-12-31 |
$7,830 |
| 2020-09-30 |
$7,154 |
| 2020-06-30 |
$6,617 |
| 2020-03-31 |
$5,879 |
| 2019-12-31 |
$4,920 |
| 2019-09-30 |
$4,982 |
| 2019-06-30 |
$4,318 |
| 2019-03-31 |
$4,879 |
| 2018-12-31 |
$11,396 |
| 2018-09-30 |
$14,409 |
| 2018-06-30 |
$14,247 |
| 2018-03-31 |
$16,608 |
| 2017-12-31 |
$13,894 |
| 2017-09-30 |
$16,146 |
| 2017-06-30 |
$15,590 |
| 2017-03-31 |
$15,877 |
| 2016-12-31 |
$16,046 |
| 2016-09-30 |
$16,602 |
| 2016-06-30 |
$15,824 |
| 2016-03-31 |
$16,155 |
| 2015-12-31 |
$16,012 |
| 2015-09-30 |
$16,857 |
| 2015-06-30 |
$16,115 |
| 2015-03-31 |
$16,707 |
| 2014-12-31 |
$16,483 |
| 2014-09-30 |
$17,407 |
| 2014-06-30 |
$17,204 |
| 2014-03-31 |
$17,665 |
| 2013-12-31 |
$16,992 |
| 2013-09-30 |
$17,811 |
| 2013-06-30 |
$16,609 |
| 2013-03-31 |
$16,462 |
| 2012-12-31 |
$16,088 |
| 2012-09-30 |
$17,062 |
| 2012-06-30 |
$15,736 |
| 2012-03-31 |
$15,907 |
| 2011-12-31 |
$14,898 |
| 2011-09-30 |
$15,126 |
| 2011-06-30 |
$13,888 |
| 2011-03-31 |
$13,785 |
| 2010-12-31 |
$12,733 |
| 2010-09-30 |
$12,647 |
| 2010-06-30 |
$11,344 |
| 2010-03-31 |
$11,077 |
| 2009-12-31 |
$9,830 |
| 2009-09-30 |
$9,993 |
| 2009-06-30 |
$9,050 |
| 2009-03-31 |
$8,968 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$790.248B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
